647 Shares of Regeneron Pharmaceuticals, Inc. $REGN Bought by Robertson Stephens Wealth Management LLC

Robertson Stephens Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 647 shares of the biopharmaceutical company’s stock, valued at approximately $491,000.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. Bank of New York Mellon Corp bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $472,950,000. Deutsche Bank AG bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $323,249,000. Finally, Man Group plc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $272,460,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 over the last ninety days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 3.3%

Shares of NASDAQ REGN opened at $807.48 on Wednesday. The firm’s 50-day simple moving average is $791.41 and its 200 day simple moving average is $721.87. The company has a market cap of $83.14 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $572.75 and a 12-month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.81 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 47.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on REGN. Wells Fargo & Company lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Truist Financial increased their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a report on Thursday, October 8th. Finally, HSBC raised their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $845.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.